This was a story about a recent study indicating that at least in the case of dialysis for individuals with acute kidney disease, more is not better. Although the story could have been clearer about the differences and definitions for chronic and acute kidney disease, it did a good job explaining that at least for the type of patients studied (those with acute kidney disease), additional dialysis failed to prevent death or rate of organ failure. It also mentioned that the additional dialysis did not improve in recovery of kidney function.
The story then went on to inform the reader that although additional dialysis did not demonstrate benefit in this type of patients, that there may be a specific confluence of medical conditions wherein additional dialysis may be appropriate.
There was no cost information provided, but the story was about the results of a study that demonstrated that more dialysis did not provide additional benefit.
The clinician quote near the end suggested that more dialysis may have benefit for certain patients but did not provide data. However – the story said that the study reported on did not find additional dialysis to provide benefit, thereby quantifying the benefit as "none"
The story qualified the information about additional dialysis not being beneficial by having a quote from a clinician indicating that there are some specific situations where additional dialysis is warranted. In so doing, the story was able to present a harm of not allowing for additional dialysis.
The evidence presented in this story comes from a study which has not yet been published, though it is available online. The story mentioned the number of people studied as well as the fact that they were randomly assigned to the different treatment groups. It included both the percentage of people in each group that died as well as the fact that the difference between the groups was found not to differ.
The story did not appear to engage in disease mongering apart from the fact that it seemed to conflate chronic and acute kidney disease.
The story included quotes from several clinicians with expertise in dialysis.
No other treatment options were mentioned, though other than refusal of treatment, there usually aren’t any. The story is about two commonly used approaches to dialysis in acutely ill patients. Decision-making is largely physician based; the over-arching decision then is dialysis or no dialysis (which because of the seriousness of the patient condition would likely be fatal).
It’s clear from the story that more versus less frequent dialysis would be based in normal clinical practice on a variety of clinical indicators (as mentioned by one of the physicians).
The story described the results of a soon-to-be published study and described this clearly. That said, it also mentioned that there had been previous studies, which were smaller and were based on outcomes from individual institutions with different outcomes from the study reported on. This provides a context for the reader to understand that the study reported on was not done in a complete vacuum of information.
Does not appear to rely on a press release.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.